Vázquez-Franco JE, Reyes-Maldonado E, Montiel-Cervantes LA, Lezama RA

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 32-39
Archivo PDF: 207.81 Kb.

RESUMEN

Introducción. La translocación t (9:22) (q34:q11)/BCR-ABL ha sido identificada como un factor de riesgo en la leucemia linfoblástica aguda (LLA) de novo. Sin embargo, hay otros factores que pueden influir en la sobrevida de los pacientes que no expresan dicha translocación. Objetivo. Relacionar la expresión y no expresión de BCR-ABL con el inmunofenotipo y otras características clínicas en pacientes adultos con LLA de población mestiza mexicana. Material y métodos. Se analizaron muestras de sangre periférica de 35 pacientes adultos con LLA de novo; a partir de éstas se realizó la detección de BCR-ABL por RT-PCR y el inmunofenotipo por citometría de flujo. Resultados. En el grupo de pacientes BCR-ABL negativos (74.28%) se distinguieron dos subgrupos con inmunofenotipos inmaduros CD34+/CD33+ y/o CD13+ y CD10-/ CD34+. En el grupo de pacientes BCR-ABL positivo (25.72 %) se encontraron blastos leucémicos con inmunofenotipo más diferenciado respecto al grupo BCR-ABL negativo. En cuanto a las características clínico-biológicas estudiadas se observó supervivencia en meses muy semejante y tendencia a presentar cuentas altas de leucocitos iniciales en ambos grupos. Conclusiones. Éste es el primer estudio realizado en población mestiza mexicana que muestra que los pacientes BCRABL negativos pueden presentar inmunofenotipos indiferenciados; por lo cual deben ser considerados como un grupo tan vulnerable como los pacientes BCR-ABL positivo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005; 80: 1517-27.

2. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-68.

3. Klco JM, Kreisel FH, Zehnbauer BA, Kulkarni S, Hassan A, Frater JL. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives. Am J Hematol 2008; 83: 901-7.

4. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007; 13: 470-81.

5. Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TF. Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood 1991; 78: 575-80.

6. Pelayo R, Welner R, Perry SS, Huang J, Baba Y, Yokota T, et al. Lymphoid progenitors and primary routes to becoming cells of the immune system. Curr Opin Immunol 2005; 17: 100-7.

7. Haferlach T, Winkemann M, Ramm-Petersen L, Meeder M, Schoch R, Weber-Matthiesen K, et al. New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the singlecell level. Br J Haematol 1997; 99: 452-9.

8. Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 2006; 20: 620-6.

9. Secker-Walker LM, Craig JM. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: a review. Leukemia 1993; 7: 147-51.

10. Playford MP, Schaller MD.The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23: 7928-46.

11. Holyoake TL, Nicolini FE, Eaves C. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. J Exp Hematol 1999; 27: 1418-27.

12. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica 2007; 92: 342-8.

13. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, et al. Definition of acute biphenotypic leukemia. Haematologica 1997; 82: 64-6.

14. Nishiuchi T, Ohnishi H, Kamada R, Kikuchi F, Shintani T, Waki F, et al. Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. Intern Med 2009; 48: 1437-41.

15. Preti HA, Huh YO, O’Brien SM, Andreeff M, Pierce ST, Keating M, et al. Myeloid markers in adult acute lymphocytic leukemia: correlations with patient and disease characteristics and with prognosis. Cancer 1995; 76: 1564-70.

16. Gleißner B, Gökbuget N, Bartram C, Janssen B, Harald R, Janssen J, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-43.

17. Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007: 435-43.

18. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gen transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED- 1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-28.

19. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-54.

20. 20 Harrison CJ, Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002; 6: 123-46.

21. Aichberger KJ, Mayerhofer M, Krauth M-T, Vales A, Kondo R, Derdak S, et al. Low-level expression of proapoptotic Bcl- 2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-44.

22. Buckle AM, Mottram R, Pierce A, Lucas GS, Russell N, Miyan JA, et al. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells. Mol Med 2000; 6: 892-902.

23. Kharas MG, Fruman DA. ABL oncogens and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005; 65: 2047-53.

24. Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG, Skorski T. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 2005; 25: 8001-8.

25. Shaoguang LI. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leukem Lymph 2008; 49: 19-26.

26. Tringali C, Lupo B, Anastasia L, Papini N, Monti E, Bresciani R, et al. Expression of Sialidase Neu2 in Leukemic K562 Cells Induces Apoptosis by Impairing Bcr-Abl/Src Kinases Signaling. J Biol Chem 2007; 282: 14364-72.

27. Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003; 102: 2014-20.

28. Nashed AL, Rao KW, Gulley ML. Clinical applications of BCR-ABL molecular testing in acute leukemia. J Mol Diagn 2003; 5: 63-72.

29. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome- positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005: 118-22.

30. Gleissner B, Goekbuget N, Rieder H, Arnold R, Schwartz S, Diedrich H, et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood 2005; 106: 4054-6.

31. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-6.

32. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. The Lancet 2008; 371: 1030-43.

33. Rozovs.kaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, Agrawal H, et al. Expression profiles of acute lymphoblastic leukemia and myeloblastic leukemias with ALL-1 rearrangements. Proc Natl Acad Sci USA 2003; 100: 7853-8.

34. Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica 2006; 91: 377-80.

35. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCRABL fusion gen in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80: 2983-90.

36. Udomsakdi-Auewarakul C, Promsuwicha O, Tocharoentanaphol C, Munhketvit C, Pattanapanyasat K, Issaragrisil S. Immunophenotypes and outcome of Philadelphia chromosome- positive and -negative Thai adult acute lymphoblastic leukemia. Int J Hematol 2003; 78: 337-43.

37. Li JL, Liu YR, Qin YZ, Chang Y, Fu JY, Wang H, et al. Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003; 11: 142-5.

38. Chen HY, Ge Z, Wu YJ, Wu LY, Sun M, Tian T, et al. Immunophenotypic analysis of Philadelphia chromosome positive acute lymphoblastic leukaemia in adults. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18: 714-7